No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Delray Medical Center Becomes First Hospital in Florida to Use New Technology for Stroke Patients

Editor: What To Know

  •   “This hospital continues to be at the forefront when it comes to the newest medical care in our community, and the RED 62™ Reperfusion Catheter &.
  • “The RED 62™ is engineered with some of the latest innovations in tracking and aspiration technology to address large vessel blockages from a stroke located in more challenging areas, while maximizing powerful aspiration to remove blood clots,” said Dr.
  •   “With the help of the BENCHMARK BMX96™ Access System, hypotube technology provides a higher stability for more complex cases when it comes to treatment of a stroke.

Delray Medical Center is the first hospital in the state of Florida to use the RED 62™ Reperfusion Catheter & BENCHMARK BMX96™ for stroke patients.  Neurointerventionalist, Dr. Dennys Reyes, is the first doctor in the county to use this technology.

The RED 62™ is designed to navigate complex distal vessel anatomy and deliver powerful aspiration along with the BENCHMARK BMX96™ to remove blood clots in acute ischemic stroke patients with large vessel occlusions. In addition, it provides faster navigation and shorter times to recanalize “brain vessels”.

“The RED 62™ is engineered with some of the latest innovations in tracking and aspiration technology to address large vessel blockages from a stroke located in more challenging areas, while maximizing powerful aspiration to remove blood clots,” said Dr. Reyes.  “With the help of the BENCHMARK BMX96™ Access System, hypotube technology provides a higher stability for more complex cases when it comes to treatment of a stroke.  In addition, when performing a procedure, the catheter is designed to increase versatility and visualization designed to help offer patients the best possible outcomes.”

As a comprehensive stroke center, Delray Medical Center has advanced technology and services to help with any neurological issues.  Our hospital is a member of the Advanced Neuroscience Network, and integrated delivery system of medical professionals and hospitals focused on offering a full continuum of neurological care throughout South Florida.

“This new technology gives patients who come to our hospital for stroke care the latest in neurologic care,” said Maggie Gill, chief executive officer of the Palm Beach Health Network & Delray Medical Center.  “This hospital continues to be at the forefront when it comes to the newest medical care in our community, and the RED 62™ Reperfusion Catheter & BENCHMARK BMX96™ is no exception.”

For more information about our neurosciences program, go to www.delraymedicalctr.com or call 561-498-4440.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy